晶纤维酸的开发 (IV) 纳米药物作为COF作为载体的抗静态剂
Shuaiqi Feng1, Yan Chen1,2, Zhifang Liu1
1Institute of Biopharmaceutical Research, State Key Laboratory of Macromolecular Drugs and Large-scale Preparation, Shandong Provincial Key Laboratory of Applied Technology for Protein and Peptide Drugs, Liaocheng University, Liaocheng 252059, P. R. China.
Journal of medicinal chemistry
|September 17, 2025
概括
这项研究开发了一种新的纳米药物,该药物向瘤并抑制胆固醇积累,导致癌症生长和转移的减少. 该药物还通过调节免疫细胞和免疫通路来增强抗瘤免疫力.
科学领域:
- 生物医学工程 生物医学工程
- 癌症生物学 癌症生物学
- 纳米医学是一种纳米医学.
背景情况:
- 失调的胆固醇积累是瘤进展和转移的关键驱动因素.
- 准胆固醇代谢是癌症治疗的一个有希望的策略.
研究的目的:
- 开发和评估一种用于向癌症治疗的新型转移素修饰纳米药物 (Tf-PEG-COFs@Pt(IV)).
- 研究纳米药物抑制胆固醇积累的能力及其对瘤生长,转移和免疫的影响.
主要方法:
- 密纤维酸 ((IV) 结合物的合成,并将其纳入转素修饰的COF基纳米载体.
- 在体外和体内对抗增殖,抗转移和免疫调节作用的评估.
- 分子机制的分析,包括DNA损伤,细胞亡,胆固醇代谢途径,表皮-介质细胞过渡和免疫细胞反应.
主要成果:
- 这种纳米药物在体外和体内表现出强大的抗增殖和抗转移活性.
- 转移素修改显著增强了瘤向.
- 这种纳米药物通过调节PPAR-α,LDLR,ACAT1和ABCA1信号来抑制胆固醇的积累.
- 它诱导了DNA损伤,引发了线粒体介导的亡,通过PI3K/AKT/mTOR途径逆转了上皮质-介质细胞过渡,并改善了瘤微环境.
- 通过增加CD3+和CD8+T细胞密度并促进M1巨细胞两极分化,增强了抗瘤免疫力.
结论:
- 开发的转移素修饰纳米药物是针对癌症向治疗的有效平台.
- 它同时针对瘤生长,转移,并通过调节胆固醇代谢和免疫反应来增强抗瘤免疫力.
相关概念视频
Hepatic Drug Clearance: Role of Transporters
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


